Dipharma Inc. Merges Kalexsyn, Inc. into Parent to Complete Integration
January 4, 2022
Dipharma Inc., part of the Dipharma Group, has merged Kalexsyn, Inc. (a Michigan corporation acquired in 2018) into its 100% owner, Dipharma Inc., effective January 1, 2022. The merger completes Kalexsyn's formal integration and strengthens Dipharma's U.S. cGMP and CRO capabilities in Kalamazoo to support services from discovery through commercialization.
- Buyers
- Dipharma Inc., Dipharma Francis (Dipharma Group)
- Targets
- Kalexsyn, Inc.
- Industry
- Pharmaceuticals
- Location
- Michigan, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
KELIX bio to Acquire Pharmaceutical Institute (PHI) in Rabat, Morocco
March 8, 2022
Pharmaceuticals
KELIX bio, a pan-African biopharmaceutical platform, entered into a binding commitment to acquire Pharmaceutical Institute (PHI), a leading pharmaceutical manufacturer in Rabat, Morocco. The deal marks KELIX bio’s first entry into Morocco and is intended to strengthen the company’s manufacturing and distribution presence as Morocco expands universal health coverage.
-
Infosys Acquires Kaleidoscope Innovation
September 3, 2020
Engineering Services
Infosys has signed a definitive agreement to acquire Kaleidoscope Innovation, a Cincinnati-based product design and development firm that serves medical, consumer and industrial markets. The acquisition expands Infosys' engineering services portfolio by adding upstream product innovation, human factors and medical device design capabilities to its global product engineering offerings.
-
Chemstream and Synthex Organics Announce Strategic Merger
October 26, 2025
Manufacturing
Chemstream announced its merger with Synthex Organics to create a combined specialty chemical solutions platform operating under the Chemstream name. The combined company will integrate Chemstream’s distribution, logistics, and fluid systems expertise with Synthex’s specialty chemical manufacturing and R&D capabilities, expanding technical resources and customer offerings across oil and gas, water treatment, and industrial markets.
-
Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio
December 11, 2024
Biotechnology
Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.
-
Symeres Acquires DGr Pharma
September 15, 2025
Healthcare Services
Symeres has acquired DGr Pharma to strengthen its early‑stage drug development and regulatory consultancy capabilities, accelerating IND‑enabling services for biopharma clients. The deal is supported by Keensight Capital, which backs Symeres and aims to expand the platform's integrated CRDMO offering across discovery and early clinical development.
-
ARCHIMED Acquires and Merges Symbio and Proinnovera to Form Symbio Proinnovera
November 17, 2023
Healthcare Services
ARCHIMED has acquired US-based Symbio and Germany-based Proinnovera in an all-equity deal and merged them to create Symbio Proinnovera, a specialized dermatology-focused CRO. The combined group will offer end-to-end dermatology consulting, formulation, testing and clinical research across North America and Europe, with founders rolling equity into the new platform and ARCHIMED-appointed operating partners joining the board to drive growth and further acquisitions.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.